Literature DB >> 23809132

Tissue factor-integrin interactions in cancer and thrombosis: every Jack has his Jill.

B Kocatürk1, H H Versteeg.   

Abstract

Tissue factor (TF) is a 47 kDa membrane protein that initiates coagulation by binding to FVII(a) and FX(a) and is a risk factor for thrombosis in many disease states. In addition to its coagulant activity, TF also influences cancer progression by triggering signaling effects via a group of G-protein coupled receptors named protease-activated receptors (PARs). TF localizes to cytoskeletal structures in migrating cells, influences cytoskeleton reorganization and promotes migration. Recently, integrins, important mediators of cell motility, have emerged as important binding partners for TF and influence both TF coagulant and PAR-2-dependent signaling functions. Direct binding of TF to integrins also impacts processes such as cell migration and signaling independent of PAR-2. A recently discovered alternatively spliced, soluble TF isoform also ligates integrins to augment angiogenesis, thus fuelling cancer progression. To date, the literature describes a complex interplay between different integrin subunits and distinct TF isoforms, but our understanding of TF-integrin bidirectional regulation remains clouded. In this review, we aim to summarize the existing knowledge on integrin-TF interaction and speculate on its relevance to physiology and pathology.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  angiogenesis inducers; beta integrins; blood coagulation factors; cell migration; protease-activated receptor 2

Mesh:

Substances:

Year:  2013        PMID: 23809132     DOI: 10.1111/jth.12222

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  15 in total

Review 1.  The coagulome and the oncomir: impact of cancer-associated haemostatic dysregulation on the risk of metastasis.

Authors:  Kate Burbury; Michael P MacManus
Journal:  Clin Exp Metastasis       Date:  2018-02-28       Impact factor: 5.150

2.  Coagulation factor VIIa-mediated protease-activated receptor 2 activation leads to β-catenin accumulation via the AKT/GSK3β pathway and contributes to breast cancer progression.

Authors:  Abhishek Roy; Shabbir A Ansari; Kaushik Das; Ramesh Prasad; Anindita Bhattacharya; Suman Mallik; Ashis Mukherjee; Prosenjit Sen
Journal:  J Biol Chem       Date:  2017-05-18       Impact factor: 5.157

3.  Regulation of alveolar procoagulant activity and permeability in direct acute lung injury by lung epithelial tissue factor.

Authors:  Ciara M Shaver; Brandon S Grove; Nathan D Putz; Jennifer K Clune; William E Lawson; Robert H Carnahan; Nigel Mackman; Lorraine B Ware; Julie A Bastarache
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

4.  Hematopoietic tissue factor-protease-activated receptor 2 signaling promotes hepatic inflammation and contributes to pathways of gluconeogenesis and steatosis in obese mice.

Authors:  Jing Wang; Sagarika Chakrabarty; Quyen Bui; Wolfram Ruf; Fahumiya Samad
Journal:  Am J Pathol       Date:  2014-12-02       Impact factor: 4.307

Review 5.  Tissue factor: a neglected role in cancer biology.

Authors:  Haiyuan Li; Yang Yu; Lei Gao; Peng Zheng; Xiaolong Liu; Hao Chen
Journal:  J Thromb Thrombolysis       Date:  2022-06-28       Impact factor: 2.300

6.  Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive D-dimer results.

Authors:  Ryuta Miyake; Yuki Yamada; Shoichiro Yamanaka; Ryuji Kawaguchi; Norihisa Ootake; Shohei Myoba; Hiroshi Kobayashi
Journal:  Mol Clin Oncol       Date:  2021-12-23

7.  Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer.

Authors:  Betül Ünlü; Begüm Kocatürk; Araci M R Rondon; Clayton S Lewis; Nathalie Swier; Rob F P van den Akker; Danielle Krijgsman; Iris Noordhoek; Erik J Blok; Vladimir Y Bogdanov; Wolfram Ruf; Peter J K Kuppen; Henri H Versteeg
Journal:  Oncogene       Date:  2022-10-21       Impact factor: 8.756

Review 8.  "Soluble Tissue Factor" in the 21st Century: Definitions, Biochemistry, and Pathophysiological Role in Thrombus Formation.

Authors:  Vladimir Y Bogdanov; Henri H Versteeg
Journal:  Semin Thromb Hemost       Date:  2015-09-26       Impact factor: 4.180

9.  CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models.

Authors:  Piyushkumar R Kapopara; Nooshin S Safikhan; Jenny L Huang; Scott C Meixner; Kevin Gonzalez; Houra Loghmani; Wolfram Ruf; Alan E Mast; Victor Lei; Edward L G Pryzdial; Edward M Conway
Journal:  J Thromb Haemost       Date:  2021-05-07       Impact factor: 16.036

10.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.